Loading clinical trials...
Loading clinical trials...
Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy
Conditions
Interventions
Pembrolizumab
Intensity Modulated Radiation Therapy
Locations
3
United States
John Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Start Date
May 16, 2016
Primary Completion Date
December 23, 2019
Completion Date
November 20, 2023
Last Updated
November 5, 2024
NCT04585750
NCT07457346
NCT06636188
NCT05526924
NCT07065630
NCT07447050
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions